MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 326909 | Name: Aclerastide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Aclerastide, also known as DSC-127; NorLeu-3-A(1-7); NorLeu-3A(1-7), is an angiotensin receptor agonist potentially for the treatment of tissue regeneration in diabetic ulcers. Administration of NorLeu3-A(1-7) reduced fibrosis and scarring in the healing wounds. This action was more pronounced with longer administration of the peptide after injury. The action of this peptide was blocked by the AT receptor antagonist d-Ala7-angiotensin(1-7), which suggests that this receptor is involved in the healing responses to exogenous NorLeu3-A(1-7). Aclerastide may have the potential in accelerating wound repair and reducing scar formation.

Chemical Structure

Aclerastide
CAS#227803-63-6

Theoretical Analysis

MedKoo Cat#: 326909

Name: Aclerastide

CAS#: 227803-63-6

Chemical Formula: C42H64N12O11

Exact Mass: 912.4818

Molecular Weight: 913.05

Elemental Analysis: C, 55.25; H, 7.07; N, 18.41; O, 19.27

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
DSC-127; DSC 127; DSC127; NorLeu-3-A(1-7); NorLeu-3A(1-7); Aclerastide; Asp-arg-nle-tyr-ile-his-pro; NorLeu3-Angiotensin.
IUPAC/Chemical Name
((S)-2-((S)-2-((S)-2-amino-3-carboxypropanamido)-5-guanidinopentanamido)hexanoyl)-L-tyrosyl-L-isoleucyl-L-histidyl-L-proline
InChi Key
RUBMHAHMIJSMHA-LBWFYSSPSA-N
InChi Code
InChI=1S/C42H64N12O11/c1-4-6-9-28(50-36(59)29(10-7-16-47-42(44)45)49-35(58)27(43)20-33(56)57)37(60)51-30(18-24-12-14-26(55)15-13-24)38(61)53-34(23(3)5-2)39(62)52-31(19-25-21-46-22-48-25)40(63)54-17-8-11-32(54)41(64)65/h12-15,21-23,27-32,34,55H,4-11,16-20,43H2,1-3H3,(H,46,48)(H,49,58)(H,50,59)(H,51,60)(H,52,62)(H,53,61)(H,56,57)(H,64,65)(H4,44,45,47)/t23-,27-,28-,29-,30-,31-,32-,34-/m0/s1
SMILES Code
O=C(O)[C@H]1N(C([C@H](CC2=CNC=N2)NC([C@H]([C@@H](C)CC)NC([C@H](CC3=CC=C(O)C=C3)NC([C@@H](NC([C@@H](NC([C@@H](N)CC(O)=O)=O)CCCNC(N)=N)=O)CCCC)=O)=O)=O)=O)CCC1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 913.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Abdallah WF, Louie SG, Zhang Y, Rodgers KE, Sivok E, S diZerega G, Humayun MS. NorLeu3A(1-7) Accelerates Clear Corneal Full Thickness Wound Healing. Invest Ophthalmol Vis Sci. 2016 Apr 1;57(4):2187-94. doi: 10.1167/iovs.15-18515. PubMed PMID: 27116546. 2: Singh N, Joshi S, Guo L, Baker MB, Li Y, Castellano RK, Raizada MK, Jarajapu YP. ACE2/Ang-(1-7)/Mas axis stimulates vascular repair-relevant functions of CD34+ cells. Am J Physiol Heart Circ Physiol. 2015 Nov 15;309(10):H1697-707. doi: 10.1152/ajpheart.00854.2014. Epub 2015 Sep 18. PubMed PMID: 26386115; PubMed Central PMCID: PMC4666983. 3: Rodgers KE, Bolton LL, Verco S, diZerega GS. NorLeu(3)-Angiotensin (1-7) [DSC127] as a Therapy for the Healing of Diabetic Foot Ulcers. Adv Wound Care (New Rochelle). 2015 Jun 1;4(6):339-345. Review. PubMed PMID: 26029484; PubMed Central PMCID: PMC4440979. 4: Balingit PP, Armstrong DG, Reyzelman AM, Bolton L, Verco SJ, Rodgers KE, Nigh KA, diZerega GS. NorLeu3-A(1-7) stimulation of diabetic foot ulcer healing: results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial. Wound Repair Regen. 2012 Jul-Aug;20(4):482-90. doi: 10.1111/j.1524-475X.2012.00804.x. Epub 2012 Jun 7. PubMed PMID: 22672145. 5: Rodgers K, Verco S, Bolton L, Dizerega G. Accelerated healing of diabetic wounds by NorLeu(3)-angiotensin (1-7). Expert Opin Investig Drugs. 2011 Nov;20(11):1575-81. doi: 10.1517/13543784.2011.619976. Epub 2011 Oct 6. Review. PubMed PMID: 21973177; PubMed Central PMCID: PMC3237292. 6: Rodgers KE, Ellefson DD, Espinoza T, Roda N, Maldonado S, Dizerega GS. Effect of NorLeu3-A(1-7) on scar formation over time after full-thickness incision injury in the rat. Wound Repair Regen. 2005 May-Jun;13(3):309-17. PubMed PMID: 15953051. 7: Rodgers KE, Espinoza T, Felix J, Roda N, Maldonado S, diZerega G. Acceleration of healing, reduction of fibrotic scar, and normalization of tissue architecture by an angiotensin analogue, NorLeu3-A(1-7). Plast Reconstr Surg. 2003 Mar;111(3):1195-206. PubMed PMID: 12621191.